← Back to Search

Cancer Vaccine

TG4050 for Head and Neck Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Transgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Newly diagnosed stage III or IVA squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
Must not have
Uncontrolled intercurrent illness
Prior exposure to cancer immunotherapy including anti-cancer vaccines, any antibody targeting T-cell co-regulatory proteins such as anti-PD1, anti-PDL1 or anti-CTLA4 antibodies
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years.
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug, TG4050, for safety and effectiveness in treating squamous cell carcinoma of the head and neck.

Who is the study for?
Adults with newly diagnosed stage III or IVA squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx who are in complete response after primary tumor treatment. Participants must be generally healthy with an ECOG performance status of 0 or 1 and have proper organ function. Excluded are those with other active cancers, prior cancer immunotherapies, HIV/AIDS, hepatitis infections, pregnant/nursing women, and recent involvement in other drug trials.
What is being tested?
The trial is testing TG4050's safety and potential effectiveness for head and neck cancer patients. It's a phase I study where participants are randomly assigned to one of two groups to receive this experimental vaccine therapy. The study is open-label meaning both researchers and participants know what treatment is being given.
What are the potential side effects?
While specific side effects for TG4050 aren't listed here as it's a new treatment under evaluation, common side effects from similar therapies may include flu-like symptoms such as fever and chills; injection site reactions; fatigue; nausea; muscle or joint pain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I have been newly diagnosed with advanced cancer in my mouth or throat.
Select...
My primary cancer is completely gone after treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any uncontrolled illnesses.
Select...
I have previously received immunotherapy for cancer.
Select...
I have tested positive for HIV/AIDS.
Select...
I have had cancer other than the one being studied in this trial.
Select...
I have a history of Hepatitis B or C.
Select...
I am currently receiving treatment for another cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase I/II: Disease-Free Survival
Phase I: Safety and tolerability (Adverse Event reported per CTCAE v5)
Secondary study objectives
Phase I/II: Distant Metastases-Free Survival
Phase I/II: Loco-Regional Relapse-Free Survival
Phase I/II: Overall Response Rate in patients with recurrent disease
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B: Study treatment initiation at recurrenceExperimental Treatment1 Intervention
TG4050 treatment initiation at the time of recurrence
Group II: Arm A : Early study treatment initiationExperimental Treatment1 Intervention
TG4050 treatment initiation at completion of primary treatment

Find a Location

Who is running the clinical trial?

TransgeneLead Sponsor
22 Previous Clinical Trials
1,588 Total Patients Enrolled

Media Library

TG4050 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04183166 — Phase 1 & 2
Squamous Cell Carcinoma Clinical Trial 2023: TG4050 Highlights & Side Effects. Trial Name: NCT04183166 — Phase 1 & 2
TG4050 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04183166 — Phase 1 & 2
Squamous Cell Carcinoma Research Study Groups: Arm A : Early study treatment initiation, Arm B: Study treatment initiation at recurrence
~31 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top